Genta Genasense NDA In Myeloma Or Leukemia Slated For Year-End Filing
Executive Summary
Genta is shifting its Genasense development focus to multiple myeloma and chronic lymphocytic leukemia with the goal of submitting an NDA for one of the oncology indications by year-end